Evaluation of Oral Tetrahydrouridine- Decitabine As Non- Cytotoxic Epigenetic Disease Modification for Sickle Cell Di...
Yogenthiran Saunthararajah, MD of Cleveland Clinic gives an overview of his abstract, Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease, that was presented at the 58th ASH Annual Meeting in San Diego, CA.
Sickle Cell
Sherif Badawy, MD @LurieChildrens #SickleCellAnemia #Cancer #Research A systematic review of quality of life in sickl...
111 Views
Andrés Cervantes, MD @AndresC27622123 @Pivotal #gastrointestialcancer #cancer #research Phase IIa trial to examine G...
Francesca Vinchi, Ph.D. @IronResearchLab @NYBloodCenter #sicklecellanemia “Breaking up” in Sickle Cell Anemia
Susanna Curtis, MD @YaleCancer @YaleMed Medical Marijuana Associated with Fewer Hospitalizations for Individuals Livi...
Improving the Lives of Americans with Sickle Cell Disease Roundtable
Sickle Cell Research #ASH19
SWAY Study @LevineCancer #ASH19
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Sickle cell disease: where we are now
Iron and inflammation in anemia and sickle cell disease
How hematologists can improve care for patients with sickle cell disease